利拉鲁肽对超重/肥胖伴血糖正常、糖尿病前期或2型糖尿病参与者淀粉酶、脂肪酶及急性胰腺炎的影响:SCALE临床开发项目汇总数据的二次分析
本研究对SCALE体重管理试验中四项试验的汇总数据(N=5358)进行二次分析,比较利拉鲁肽3.0 mg、1.8 mg与安慰剂对淀粉酶/脂肪酶水平及急性胰腺炎(AP)事件的影响。结果显示利拉鲁肽导致剂量无关、可逆的淀粉酶/脂肪酶升高,且不能预测AP发生;胆结石可能贡献了50%的AP病例。
要点
- 利拉鲁肽3.0 mg较安慰剂使淀粉酶平均升高7%、脂肪酶平均升高31%,1.8 mg有类似变化。
- 利拉鲁肽3.0 mg组淀粉酶/脂肪酶升高≥正常上限的比例高于安慰剂组,但≥3倍正常上限者极少。
- 停药后酶水平恢复基线;酶升高对AP的阳性预测值极低(<1%)。
核心结论
- 利拉鲁肽引起剂量无关、可逆的淀粉酶/脂肪酶活性升高,与基线特征无关,不预测AP发生;胆结石可能贡献了50%的AP病例;除怀疑AP外,数据不支持监测淀粉酶/脂肪酶水平。
研究设计与样本
- 对四项SCALE体重管理试验的汇总数据进行二次分析,共纳入5358例BMI≥30或27至<30 kg/m²且伴≥1种合并症者。
- 其中血糖正常1723例,糖尿病前期2789例,2型糖尿病846例。
- 参与者随机分配至利拉鲁肽3.0 mg(n=3302)、利拉鲁肽1.8 mg(n=211,仅2型糖尿病)或安慰剂(n=1845)。
主要发现
- 56周内,利拉鲁肽3.0 mg较安慰剂使淀粉酶平均升高7%、脂肪酶平均升高31%;利拉鲁肽1.8 mg观察到类似变化。
- 利拉鲁肽3.0 mg组较安慰剂组更多参与者出现淀粉酶(9.4% vs 5.9%)和脂肪酶(43.5% vs 15.1%)升高≥正常上限(ULN);淀粉酶≥3×ULN者极少(利拉鲁肽3.0 mg或安慰剂均<0.1%),脂肪酶≥3×ULN者为2.9% vs 1.5%。
- 停用利拉鲁肽后酶水平恢复至基线。
- 13例发生AP:12例在利拉鲁肽3.0 mg治疗期间(n=9,0.3%)或之后(n=3,0.1%),1例(0.1%)在安慰剂组;13例中6例(利拉鲁肽5例,安慰剂1例)在AP发生时存在胆结石。
- AP发生前淀粉酶/脂肪酶升高≥1×ULN或≥3×ULN对AP的阳性预测值极低(<1%)。
临床怎么用
- 原文结论指出,除怀疑AP外,数据不支持在利拉鲁肽治疗中监测淀粉酶/脂肪酶水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe amylase/lipase activity levels and events of acute pancreatitis (AP) in the SCALE (Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes) weight-management trials. RESEARCH DESIGN AND METHODS: Secondary analyses were performed on pooled data from four trials (N = 5,358 with BMI ≥30, or 27 to <30 kg/m2 with ≥1 comorbidity). Of these, 1,723 had normoglycemia, 2,789 had prediabetes, and 846 had type 2 diabetes. Participants were randomized to liraglutide 3.0 mg (n = 3,302), liraglutide 1.8 mg (n = 211, only type 2 diabetes), or placebo (n = 1,845). Relationships between baseline characteristics and amylase/lipase activity at baseline and during treatment were investigated. RESULTS: Over 56 weeks, liraglutide 3.0 mg versus placebo was associated with increases in mean levels of 7% (amylase) and 31% (lipase), respectively. Similar changes in amylase/lipase levels were observed with liraglutide 1.8 mg. More participants receiving liraglutide 3.0 mg versus placebo experienced amylase (9.4% vs. 5.9%) and lipase (43.5% vs. 15.1%) elevations greater than or equal to the upper limit of normal (ULN); few had elevations ≥3 × ULN for amylase (<0.1% with liraglutide 3.0 mg or placebo) or lipase (2.9% vs. 1.5%, respectively). After liraglutide discontinuation, enzymes returned to baseline levels. Thirteen participants developed AP: 12 on (n = 9, 0.3%) or after (n = 3, 0.1%) liraglutide 3.0 mg treatment and one (0.1%) with placebo. A total of 6/13 participants with AP (5/12 liraglutide; 1 placebo) had gallstone disease evident at AP onset. Amylase/lipase elevations either 1 × ULN or ≥3 × ULN before AP onset had very low positive predictive value for AP (<1%). CONCLUSIONS: Liraglutide resulted in dose-independent, reversible increases in amylase/lipase activity, unrelated to baseline characteristics, not predicting AP onset. Gallstones possibly contributed to 50% of AP cases. Data provide no basis for amylase/lipase level monitoring in liraglutide treatment except in suspected AP.
引用
- Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017. PMID: 28473337. doi:10.2337/dc16-2684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。